FDA Roundup: January 10, 2025

SILVER SPRING, Md., Jan. 10, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:

    --  Today the FDA released a Long-Term National Strategy to Increase the
        Resiliency of the U.S. Infant Formula Market. The strategy builds on the
        Immediate National Strategy to Increase the Resiliency of the U.S.
        Infant Formula Market that was released in early 2023 in direct response
        to the February 2022 infant formula recall and the subsequent shortage
        of infant formula in the U.S. The FDA also partnered with the National
        Academies of Sciences, Engineering and Medicine, as directed by
        Congress, to further study challenges in the infant formula market in
        the U.S. in order to inform a long-term strategy. The long-term strategy
        focuses on our long-term goal of achieving a more robust and nimble U.S.
        infant formula supply and identifies actions we have taken since
        2023."Consumers deserve to have the utmost confidence that infant
        formula available in the U.S. is safe and nutritious," said Jim Jones,
        FDA Deputy Commissioner for Human Foods. "We are proud of the actions we
        have taken to protect the integrity of the infant formula supply chain.
        We also recognize that additional efforts are needed and are committed
        to continued stakeholder engagement and increased oversight of the U.S.
        infant formula market."


    --  On Wednesday, the FDA published the FDA Voices, "CDER Brings Many Safe
        and Effective Therapies to Patients and Consumers in 2024," by Patrizia
        Cavazzoni, M.D., Director, Center for Drug Research and Evaluation
        (CDER). This FDA Voices covers highlights from the 2024 New Drug Therapy
        Approvals report, also published on Wednesday. The report features drug
        approvals that CDER considers likely to have a significant impact on
        public health. The 2024 report includes approvals for therapies that
        collectively treat a wide range of conditions, including a
        first-in-class drug for schizophrenia, three novel antibiotics and new
        drugs for many types of cancer.


    --  On Wednesday, the FDA released a Request For Comments (RFC) soliciting
        public input on new opportunities and emergent monitoring needs for
        possible inclusion in the forthcoming National Antimicrobial Resistance
        Monitoring System (NARMS) 2026-2030 Strategic Plan. The Federal Register
        notice about the RFC includes instructions for submitting comments, as
        well as specific questions and requests for information meant to prompt
        helpful submissions. The agency will be accepting public comments
        through March 26, 2025.


    --  On Wednesday, the FDA published the Create and Keep a Medication List
        for Your Health Consumer Update. Many people of all ages take
        medications. Keeping track of when, how and why you use medications is
        important for your health and safety. A medication list is a tool to
        help you keep track of all the prescription medications, OTC drugs,
        vitamins and supplements that you take. Keeping a medication list helps
        health care professionals know about your current health and minimize
        medication errors and adverse drug interactions. It can be a lifesaving
        tool, especially during an emergency.
    --  On Wednesday, the FDA updated the outbreak advisory for Salmonella
        Typhimurium infections linked to cucumbers. Epidemiologic and traceback
        information demonstrated that American/slicer cucumbers grown by
        Agrotato, S.A. de C.V. in Sonora, Mexico were the source of illnesses in
        this outbreak. Several companies issued recalls for American/slicer
        cucumbers and products containing recalled cucumbers during the
        investigation. CDC has now declared the outbreak over, and the FDA's
        investigation is closed.

Additional Resources:

    --  FDA Newsroom

Media Contact: FDA Office of Media Affairs, 301-796-4540
Consumer Inquiries: 888-INFO-FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.

View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-roundup-january-10-2025-302348318.html

SOURCE U.S. Food and Drug Administration